title: TLR9 ligand CpG-ODN applied to the injured mouse cornea elicits retinal inflammation.
abstract: During bacterial and viral infections, unmethylated CpG-DNA released by proliferating and dying microbes is recognized by toll-like receptor (TLR) 9 in host cells, initiating innate immune responses. Many corneal infections occur secondary to epithelial breaches and represent a major cause of vision impairment and blindness globally. To mimic this clinical situation, we investigated mechanisms of TLR9 ligand-induced corneal inflammation in mice after epithelial debridement. Application of CpG oligodeoxynucleotides (ODNs) resulted in neutrophil and macrophage infiltration to the cornea and loss of transparency. By 6 hours after CpG-ODN administration, TLR9 mRNA was increased in the cornea and retina. In vivo clinical examination at 24 hours revealed inflammatory infiltrates in the vitreous and retina, which were confirmed ex vivo to be neutrophils and macrophages, along with activated resident microglia. CpG-ODN-induced intraocular inflammation was abrogated in TLR9(-/-) and macrophage-depleted mice. Bone marrow reconstitution of irradiated TLR9(-/-) mice with TLR9(+/+) bone marrow led to restored corneal inflammatory responses to CpG-ODN. Fluorescein isothiocyanate-CpG-ODN rapidly penetrated the cornea and ocular media to reach the retina, where it was present within CD68(+) retinal macrophages and microglia. These data show that topically applied CpG-ODN induces intraocular inflammation owing to TLR9 activation of monocyte-lineage cells. These novel findings indicate that microbial CpG-DNA released during bacterial and/or viral keratitis can cause widespread inflammation within the eye, including the retina.
authors.affiliation: Department of Anatomy and Developmental Biology, School of Biomedical Sciences, Monash University, Clayton, VIC, Australia.
authors.forename: Holly R
authors.initials: HR
authors.lastname: Chinnery
authors.forename: Samuel
authors.initials: S
authors.lastname: McLenachan
authors.forename: Nicolette
authors.initials: N
authors.lastname: Binz
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: John V
authors.initials: JV
authors.lastname: Forrester
authors.forename: Mariapia A
authors.initials: MA
authors.lastname: Degli-Esposti
authors.forename: Eric
authors.initials: E
authors.lastname: Pearlman
authors.forename: Paul G
authors.initials: PG
authors.lastname: McMenamin
mesh_terms: D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics / Q000633:toxicity*; D000818:Animals; D003315:Cornea / Q000276:immunology; D065306:Corneal Injuries; D007113:Immunity, Innate / Q000502:physiology; D007634:Keratitis / Q000139:chemically induced / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D020556:Neutrophil Infiltration; D009838:Oligodeoxyribonucleotides / Q000493:pharmacokinetics / Q000633:toxicity*; D012173:Retinitis / Q000139:chemically induced*; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D051217:Toll-Like Receptor 9 / Q000502:physiology*
chemical_list: D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D008070:Lipopolysaccharides; D009838:Oligodeoxyribonucleotides; D051197:Toll-Like Receptor 4; D051217:Toll-Like Receptor 9
references.citation: Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1599-608
references.pmid: 18385080
references.citation: Infect Immun. 2007 Dec;75(12):5908-15
references.pmid: 17875630
references.citation: Infect Immun. 2006 Sep;74(9):5325-32
references.pmid: 16926427
references.citation: Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1568-74
references.pmid: 17389486
references.citation: Immunol Cell Biol. 2005 Jun;83(3):301-6
references.pmid: 15877609
references.citation: PLoS One. 2009 Nov 20;4(11):e7945
references.pmid: 19936204
references.citation: Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4209-16
references.pmid: 16249500
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8944-9
references.pmid: 12060721
references.citation: Nature. 1997 Jul 24;388(6640):394-7
references.pmid: 9237759
references.citation: Invest Ophthalmol Vis Sci. 2005 Feb;46(2):497-503
references.pmid: 15671274
references.citation: Invest Ophthalmol Vis Sci. 2006 Jan;47(1):241-8
references.pmid: 16384969
references.citation: J Gene Med. 2009 Sep;11(9):782-90
references.pmid: 19533588
references.citation: J Immunol. 2010 Oct 1;185(7):4272-83
references.pmid: 20826748
references.citation: Br J Ophthalmol. 1995 Sep;79(9):834-40
references.pmid: 7488603
references.citation: Eur J Immunol. 2001 Jul;31(7):2154-63
references.pmid: 11449369
references.citation: Nature. 2000 Dec 7;408(6813):740-5
references.pmid: 11130078
references.citation: Annu Rev Immunol. 2009;27:119-45
references.pmid: 19302036
references.citation: Transplantation. 2004 Jun 15;77(11):1641-6
references.pmid: 15201661
references.citation: J Immunol. 2003 May 15;170(10):5219-27
references.pmid: 12734370
references.citation: Prog Retin Eye Res. 2010 May;29(3):169-90
references.pmid: 20206286
references.citation: Ophthalmol Eye Dis. 2009 Nov 25;1:45-54
references.pmid: 20431695
references.citation: J Immunol. 2005 May 1;174(9):5193-200
references.pmid: 15843514
references.citation: PLoS Pathog. 2010 Jul 01;6:e1000976
references.pmid: 20617171
references.citation: J Neuroimmunol. 2006 Oct;179(1-2):46-52
references.pmid: 16884784
references.citation: J Immunol. 2001 Oct 15;167(8):4616-26
references.pmid: 11591791
references.citation: J Immunol. 2009 Mar 1;182(5):2738-44
references.pmid: 19234168
references.citation: FASEB J. 2004 Feb;18(2):412-4
references.pmid: 14688201
references.citation: Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1247-54
references.pmid: 18936141
references.citation: J Virol. 2007 Oct;81(20):11128-38
references.pmid: 17686871
references.citation: Bull World Health Organ. 2001;79(3):214-21
references.pmid: 11285665
references.citation: J Leukoc Biol. 2003 Aug;74(2):172-8
references.pmid: 12885933
references.citation: Immunology. 2008 Dec;125(4):541-8
references.pmid: 18540963
references.citation: Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1701-10
references.pmid: 17389502
references.citation: Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2264-71
references.pmid: 12091426
references.citation: Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1980;213(4):221-33
references.pmid: 7006439
references.citation: Nat Immunol. 2004 Feb;5(2):190-8
references.pmid: 14716310
references.citation: Nature. 1980 Aug 7;286(5773):611-3
references.pmid: 7402339
references.citation: Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4910-6
references.pmid: 17065506
references.citation: J Leukoc Biol. 2004 Apr;75(4):612-23
references.pmid: 14726498
references.citation: Eur J Immunol. 2003 Jun;33(6):1633-41
references.pmid: 12778481
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Biochem Biophys Res Commun. 2002 Jul 12;295(2):336-41
references.pmid: 12150953
references.citation: J Immunol. 2002 May 15;168(10):4854-63
references.pmid: 11994434
references.citation: Invest Ophthalmol Vis Sci. 2005 Feb;46(2):589-95
references.pmid: 15671286
references.citation: Stem Cells. 2005 Apr;23(4):507-15
references.pmid: 15790772
references.citation: Immunol Rev. 2010 Mar;234(1):282-304
references.pmid: 20193026
references.citation: Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3043-8
references.pmid: 10967062
references.citation: J Virol. 2003 Sep;77(18):10037-46
references.pmid: 12941914
references.citation: Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2278-84
references.pmid: 12091428